Last reviewed · How we verify
NCT05627739
A Study of Mycophenolate Mofetil Combined With Glucocorticoid Therapy in Relapse Vogt-Koyanagi-Harada Disease
trial testing Mycophenolate Mofetil in Vogt-Koyanagi-Harada Disease in 15 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Tianjin Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 October 2021 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Conditions studied
- Vogt-Koyanagi-Harada Disease — all drugs for Vogt-Koyanagi-Harada Disease →
- Mycophenolate Mofetil — all drugs for Mycophenolate Mofetil →
Sponsor
Tianjin Medical University
Who can join
Adults 18 to 70, any sex, with Vogt-Koyanagi-Harada Disease or Mycophenolate Mofetil. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is designed to test the hypothesis that Mycophenolate Mofetil is clinically useful for patients with relapse Vogt-Koyanagi-Harada disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05627739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mycophenolate Mofetil
Trials testing the same drug.
- NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
- NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07524530 — Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers · Phase 2 · not yet recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
Other recruiting trials for Vogt-Koyanagi-Harada Disease
Currently open trials in the same condition.
- NCT05590416 — A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease · recruiting
Other Tianjin Medical University trials
Trials by the same sponsor.
- NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
- NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
- NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05627739 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627739.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing